Company Interview / LTR Pharma (ASX: LTP) Investor Presentation

LTR Pharma (ASX: LTP) is a Clinical Stage Biopharmaceutical Company Pioneering a novel intranasal technology – SPONTAN® – designed to treat Erectile Dysfunction in 10 minutes or less. LTR Pharma is commercialising a ‘First in Class’ rapid treatment for Erectile Dysfunction (ED) SPONTAN® with fast-track US NDA Filing within two years.

LTR Pharma COO Peter McLennan details how he recent $25 million capital raise will fuel LTR's US expansion, and help bring about commercialisation, along with regulatory engagements with the US FDA and TGA.

*The information contained in this event is general in nature and is not intended as advice. Before acting on information you've seen or heard at this event, you should seek professional financial advice which takes into account your personal circumstances.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD